Lokavant

Your guide to decentralized trials and their impact on enrollment

The pandemic has driven rapid adoption of decentralized clinical trials, but measuring the effectiveness and risk of these efforts on enrollment has been difficult to date.​​

Lokavant partnered with THREAD to conduct the first ever impact analysis of DCTs on key performance indicators during the pandemic. Using proprietary data from over 300 ongoing COVID-impacted trials and data from THREAD, Lokavant’s analytical platform showcased the ability of decentralized approaches to mitigate COVID-related risks.

In this report, you will find:

  • Enrollment and subject discontinuation rates for the industry and THREAD during the pandemic
  • Value drivers of advanced benchmarking for DCTs
  • Recommendations for industry on DCT prevalence beyond the pandemic
Illustration
Lokavant
The first data-driven evaluation of the impact of decentralized approaches during COVID​
Enter your information below to see the report

Sumitovant
Thread research owler
perficient
Halloran
ELOXX
Parexel Master
Roivant Sciences
Ergomed